News – Page 1066 – Endpoints News

Under pressure to perform, Woodford counterattacks against Sahm Adrangi's latest short assault

8 years ago

Trailing GSK, AstraZeneca offers an encouraging look at PhIII data for three-in-one COPD inhaler

8 years ago

Fast-growing Shanghai Pharma to plant foot in San Diego, hunting deals in US and Europe

8 years ago

Duchenne MD dad pivots from last-minute alert on FDA's partial hold to $125M IPO for Solid Bio

8 years ago

Summit shares shoot up on positive DMD PhII; AstraZeneca and allies back a new incubator/accelerator at Babraham

8 years ago

Women’s health biotech KaNDy dickering with Allergan about a $400M buyout deal — report

8 years ago

Menlo bags $119M IPO on promise of ex-Merck drug

8 years ago

Takeda and Zinfandel write off yet another Alzheimer’s PhIII after Actos fails a key interim test

8 years ago

Biogen makes a buyout deal, but it’s not the big one you’ve been waiting for

8 years ago

Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer's

8 years ago

In a breakthrough, Chinese researchers clone monkeys hoping to provide better disease models

8 years ago

GW on fire: PhIII epilepsy data signals success ahead for first CBD drug

8 years ago

Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal

8 years ago

Ex-Allergan team at Bonti raises $15.5M for another neurotoxin; Shire commits to publishing in open access journals ...

8 years ago

The new serial entrepreneur in the biotech arena launches another upstart looking to drug RNA

8 years ago

Pfizer’s latest copycat could put the squeeze on Roche — again

8 years ago

Big day looming, Novartis' new CEO Vas Narasimhan readies his jump into a marketing melee

8 years ago

When VCs hand out mega-rounds to Vir and Gossamer, are they betting on the jockey or the horse?

8 years ago

Reckoning the potential of CRISPR/Cas9 tech, NIH launches $190M genome editing research initiative

8 years ago

Puma Biotechnology shares tank after CHMP looks ready to hit a red light on neratinib

8 years ago

Incyte tries to fend off TRC's mini-tender offer to investors; Gritstone Oncology scoops Actelion CFO Jean-Marc ...

8 years ago

Pancreatic cancer combo sees high survival rates in ChemoCentryx PhIb data

8 years ago

J&J’s move to cut Remicade price cost some big bucks, but guarded against Pfizer’s copycat

8 years ago

Allied with Penn, Tmunity’s cell therapy pioneers bag $100M mega-round to back a breakthrough quest on CAR-T, ...

8 years ago

First page Previous page 1063 1064 106510661067 1068 1069 Next page Last page